CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update

    NEXT STORY
    U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy
    PREV STORY
    Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    BeiGene Announces Proposed Public Offering

    CAMBRIDGE, Mass. and BEIJING, China, Jan. 16, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a ...

    author_avatar
    NASDAQ Market News

    Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results and Recent Corporate Developments

    -- Fourth quarter 2017 EXONDYS 51® (eteplirsen) total net revenues of $57.3 million -- ...

    author_avatar
    NASDAQ Market News

    FDA grants Roche’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer

    author_avatar
    NASDAQ Market News